Compare PTCT & NOVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | NOVT |
|---|---|---|
| Founded | 1998 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.0B |
| IPO Year | 2006 | 1999 |
| Metric | PTCT | NOVT |
|---|---|---|
| Price | $63.51 | $143.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 3 |
| Target Price | $101.07 | ★ $194.50 |
| AVG Volume (30 Days) | ★ 1.2M | 360.5K |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.48 | N/A |
| EPS | ★ 0.90 | 0.82 |
| Revenue | $264,734,000.00 | ★ $521,290,000.00 |
| Revenue This Year | N/A | $15.57 |
| Revenue Next Year | $9.26 | $15.87 |
| P/E Ratio | ★ $71.38 | $173.98 |
| Revenue Growth | ★ 36.19 | 35.49 |
| 52 Week Low | $61.23 | $98.27 |
| 52 Week High | $90.87 | $176.38 |
| Indicator | PTCT | NOVT |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 49.53 |
| Support Level | $62.46 | $141.72 |
| Resistance Level | $72.86 | $150.66 |
| Average True Range (ATR) | 2.00 | 5.19 |
| MACD | 0.19 | 0.24 |
| Stochastic Oscillator | 38.57 | 48.75 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.